Navigation Links
Cellectar, Inc. Begins GMP Production
Date:8/18/2008

Radiopharmaceutical production facility to support clinical development for

lead drug candidate and other molecules

MADISON, Wis., Aug. 18 /PRNewswire/ -- Cellectar, Inc., a privately-held radiopharmaceutical company that designs, develops and manufactures products to detect, treat and monitor human cancers, today announced that it has completed commissioning its in-house manufacturing capability to meet clinical trial needs in compliance with Good Manufacturing Practice (GMP) requirements. This capability will allow Cellectar to initiate and complete its clinical trials while remaining independently able to develop and manufacture new radiopharmaceuticals beyond its lead candidate, CLR1404. With this unique capability in place, Cellectar is now actively looking to expand its portfolio both with internal candidates and through potential in-licensing opportunities.

"We are extremely gratified to have achieved GMP compliance in our radiopharmaceutical manufacturing facility because it takes us one step closer toward clinical trials with our lead drug candidate, CLR1404," commented Neal Sandy, Chief Operating Officer at Cellectar. "Our manufacturing technology and custom-designed building, provide the flexibility and opportunity for our growing company to supply the radiopharmaceuticals needed to support our clinical program and to continue the development of additional molecules."

Cellectar's lead drug candidate, CLR1404, is a phospholipid ether (PLE) analog radiolabeled with iodine-131, a radioactive isotope commonly used to treat cancer. In pre-clinical evaluations, CLR1404 has shown the ability to carry the potent isotope inside malignant cells and destroy them without adversely affecting healthy tissues. Human trials will begin later this year following submission and FDA review of Cellectar's Investigational New Drug (IND) application.

Cellectar's initial clinical trial will focus on assessing safety and appropriate dosing in the treatment of a variety of solid tumors.

About Cellectar

Cellectar, Inc. is a radiopharmaceutical company that designs, develops and manufactures products to detect, treat and monitor a wide variety of human cancers. Cellectar's novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs) analogs, with radioisotopes that can either image or destroy malignant cells. Cellectar's products' unique mechanism of action is based on their accumulation and selective retention in malignant tumors and not in normal cells. The company's operations are based in Madison, WI. Cellectar has previously raised approximately $22.0 million from angel and venture capital investors; including Continuum Investment Partners and Venture Investors, LLC. For further information about Cellectar, visit the company's website at http://www.cellectar.com.


'/>"/>
SOURCE Cellectar, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectar, Inc. Raises $13 Million in Private Offering
2. GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season
3. China Biologic Products Begins Annual Maintenance of its Production Facilities
4. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
5. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
6. China Biologic Products Begins Operation of its Newly Constructed Plasma Collection Station in Qi He County, Shandong Province
7. Medimetriks Pharmaceuticals, Inc. Begins Operations
8. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
9. Nikon Instruments Begins Direct Sales and Technical Support in Southern California and Rocky Mountain Territories
10. Thomson Scientific Begins Expansion of Web of Science
11. Ohio Task Force Begins Mission of Creating a New 21st Century Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a range ... place between the two entities said Poloz. Speaking ... Ottawa , he pointed to the country,s inflation ... federal government. "In ... "Both institutions have common economic goals, why not sit down ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):